Navigation Links
Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice,with Transplant of Purified Donor Blood Stem Cells

autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.

About Cellerant

Cellerant Therapeutics is a commercial-stage company developing a portfolio of products and services focused on the regulation of the hematopoietic (blood-forming) system. Our products are based on adult hematopoietic stem and progenitor cells as both therapeutic agents and targets for drug discovery. Visit our website at http://www.cellerant.com.

Contact

Cellerant Therapeutics, Inc.
Bruce Cohen, 650-232-2122
or
MacDougall Biomedical Communications
Kari Watson, 508-647-0209
kari@macbiocom.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...tudy shows the Prox1 gene is a two-way switch that...s to be reprogrammed so that they lose their ident..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNew...rch Hospital have discovered that a certain differ...ity that it requires the constant expression of a ...
(Date:12/1/2008)...ec. 1 GeoVax Labs, Inc.,...echnology company developing,human vaccines for d...rus) and,other infectious agents, announced today...ials will take place in twelve sites across North ...collaboration with The National Institutes of,Hea...
(Date:11/28/2008)...IS, Nov. 28 Eli Lilly an...mental New Drug Application (sNDA) from,the U.S. ... (duloxetine HCl),for the management of chronic p...he first half of 2009, adding data from a recently...is pain of the knee. , The decision does no...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Chocolate Milk 3A The Official Drink of Halloween 2863 1Chocolate Milk 3A The Official Drink of Halloween 2863 2Chocolate Milk 3A The Official Drink of Halloween 2863 3Chocolate Milk 3A The Official Drink of Halloween 2863 4Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 1Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 2Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2858 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 1Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 2Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 3Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 4Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 5Hyperion Therapeutics Inc Announces Senior Management Team and 2415M Financing Event 1052 6Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 1Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 445 6
...e Skeletal Muscle More,Efficiently than Male Cells...e stem cells,derived from muscle have a greater ab...le cells, according to a study at Children,s,Hospi...eing published in the April 9 issue of the,Journal...fference,in regenerative capabilities of muscle st...
...007 - Inotek,Pharmaceuticals Corporation announced...eclinical animal data showing that the,administrat...tor,has a large protective effect on the survival ... a nuclear enzyme that directs the,repair of damag...epair enzymes and has potential applications for t...
Other Medicine Technology:The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 2The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 3Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3
(Date:12/2/2008)...iginal Special Features MLS Stars and Promotes Hea...re/ -- Juniper Content Corporation,s (OTC Bulleti... fastest-growing Spanish-language children,s netwo...al special Juega Como un MLS Pro , the climax of ...ague Soccer, on Sunday, December 7th at 7 PM EST. ...
(Date:12/2/2008)...CKVILLE, Md., Dec. 2 Neu...oday that it has entered into a,collaboration wit...aiwan, to,advance development of Neuralstem,s hum...ollaboration will focus on Amyotrophic Lateral Scl...nn-Zong Lin, MD, PhD as principle,investigator. ,...
(Date:12/2/2008)...LVERN, Pa., Dec. 2 Arlington Medic...intelligence for the pharmaceutical and diagnostic...sen Pharmaceuticals, Levaquin,is the preferred qu...eral,medical-surgical hospitals in the United Sta..., sinus, skin and urinary tract infections caused ...
(Date:12/2/2008)...rcentage of Biologic-Treated Psoriasis Patients Wi...Decision Resources , , WALTHAM, Mass., Dec....world,s leading research and advisory firms for ph...logic agents, particularly Centocor/Janssen-Cilag,...e moderate to severe psoriasis drug market to more...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...alian Medical Association (AMA) has issued a warni...tly trained doctors //in the future due to a lack ...MA president has written to the federal MPs and se... in place that would help to deal with the increas...
... health authorities are reconsidering recent chang...doctors of Indian origin ineligible// to work in t...th (DoH) and the home office had put in place a ne... to prove that no suitable candidate was available...
...me the scarcity of doctors in rural areas, the Goa...assing out of state-run medical colleges// to serv...ratapsingh Rane said. The state cabinet decided ...d to be signed by the medical students to serve in...
...rs have found for the first time that human embryo...coaxed to develop into mature T-cells//, raising h...s from the UCLA AIDS Institute and the Institute f... found that it is possible to convert human embryo...
Other Medicine News:Health News:Britain Reconsidering New Visa Rules for Indian Doctors 2Health News:T-cells Developed from Human Embryonic Stem Cells 2
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Small, comes in a compact carrying case, carrying pouch included.
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure.
Medicine Products: